NTLA


Line plots across dimensions of each concept
Tables

Table of contents



us-gaap:CommonStockValue
us-gaap:CounterpartyName, us-gaap:SubsidiarySaleOfStock, us-gaap:TypeOfArrangement
us-gaap:CommonStockParOrStatedValuePerShare
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement
us-gaap:SubsidiarySaleOfStock, us-gaap:TypeOfArrangement

us-gaap:CommonStockSharesIssued

us-gaap:CommonStockSharesAuthorized

us-gaap:CommonStockSharesOutstanding
us-gaap:StatementEquityComponents

us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted

us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecurities
us-gaap:AwardType

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

us-gaap:CostsAndExpenses

us-gaap:ResearchAndDevelopmentExpense

us-gaap:GeneralAndAdministrativeExpense

us-gaap:OperatingIncomeLoss

us-gaap:AllocatedShareBasedCompensationExpense
us-gaap:IncomeStatementLocation

us-gaap:ProfitLoss

us-gaap:NetIncomeLoss
us-gaap:StatementEquityComponents

us-gaap:ComprehensiveIncomeNetOfTax

us-gaap:Assets

us-gaap:LiabilitiesAndStockholdersEquity

us-gaap:StockholdersEquity
us-gaap:StatementEquityComponents

us-gaap:AssetsCurrent

us-gaap:CashAndCashEquivalentsAtCarryingValue

us-gaap:AccountsReceivableNetCurrent

us-gaap:PrepaidExpenseAndOtherAssetsCurrent

us-gaap:PropertyPlantAndEquipmentNet

us-gaap:OperatingLeaseRightOfUseAsset

us-gaap:OtherAssetsNoncurrent

us-gaap:LiabilitiesCurrent

us-gaap:AccountsPayableCurrent

us-gaap:OtherAccruedLiabilitiesCurrent

us-gaap:AccruedLiabilitiesCurrent

us-gaap:OperatingLeaseLiabilityCurrent

us-gaap:ContractWithCustomerLiabilityCurrent

us-gaap:OperatingLeaseLiabilityNoncurrent

us-gaap:StockholdersEquity
us-gaap:StatementEquityComponents

us-gaap:CommonStockValue

us-gaap:AdditionalPaidInCapitalCommonStock

us-gaap:RetainedEarningsAccumulatedDeficit

us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax

us-gaap:StockIssuedDuringPeriodValueNewIssues
us-gaap:CounterpartyName, us-gaap:StatementEquityComponents, us-gaap:SubsidiarySaleOfStock
us-gaap:CounterpartyName, us-gaap:SubsidiarySaleOfStock
us-gaap:CounterpartyName, us-gaap:SubsidiarySaleOfStock, us-gaap:TypeOfArrangement
us-gaap:StatementEquityComponents
us-gaap:StatementEquityComponents, us-gaap:SubsidiarySaleOfStock
us-gaap:SubsidiarySaleOfStock

us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
us-gaap:StatementEquityComponents

us-gaap:NetCashProvidedByUsedInOperatingActivities

us-gaap:NetCashProvidedByUsedInInvestingActivities

us-gaap:NetCashProvidedByUsedInFinancingActivities

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

us-gaap:NetCashProvidedByUsedInOperatingActivities

us-gaap:NetIncomeLoss
us-gaap:StatementEquityComponents

us-gaap:ProfitLoss

us-gaap:DepreciationDepletionAndAmortization

us-gaap:IncreaseDecreaseInAccountsReceivable

us-gaap:ShareBasedCompensation

us-gaap:NetCashProvidedByUsedInInvestingActivities

us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

us-gaap:NetCashProvidedByUsedInFinancingActivities

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
us-gaap:AwardType

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
us-gaap:CounterpartyName, us-gaap:FinancialInstrument, us-gaap:TypeOfArrangement
ntla:ContractWithCustomerLiabilityAdditions
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

ntla:DecreaseInAccountsReceivables

ntla:IncreaseDecreaseInOperatingLeaseLiabilities

ntla:IncreaseDecreaseInOperatingRightOfUseAssets

ntla:IncreaseInAccountsReceivables
us-gaap:CounterpartyName, us-gaap:Range, us-gaap:TypeOfArrangement
ntla:IncreaseInTargetCap
us-gaap:IncomeStatementLocation, us-gaap:TypeOfArrangement
ntla:LegalAccountingAndOtherFees
us-gaap:CounterpartyName, us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByType, us-gaap:TypeOfArrangement
ntla:PaymentOfRoyaltyPercentageOnNetProductSales
us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByType, us-gaap:TypeOfArrangement
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement
ntla:PaymentsDueFromAffiliates
us-gaap:TypeOfArrangement
ntla:PercentageOfGrossProceedsFromCommonStockAsSalesAgentCashCommission
us-gaap:CounterpartyName, us-gaap:SubsidiarySaleOfStock, us-gaap:TypeOfArrangement
ntla:PercentageOfPremiumOverVolumeWeightedAverageTradingPriceOfCommonStockDuring30DayPeriodPriorToClosingOfEquityTransaction
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments

us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
us-gaap:SubsidiarySaleOfStock

us-gaap:CapitalExpendituresIncurredButNotYetPaid

us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized

us-gaap:ContractWithCustomerLiabilityRevenueRecognized

us-gaap:EarningsPerShareBasicAndDiluted

us-gaap:IncreaseDecreaseInAccountsPayable

us-gaap:IncreaseDecreaseInAccruedLiabilities

us-gaap:IncreaseDecreaseInContractWithCustomerLiability

us-gaap:IncreaseDecreaseInOtherOperatingAssets

us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

us-gaap:InvestmentIncomeInterest

us-gaap:MarketableSecuritiesUnrealizedGainLoss

us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
us-gaap:StatementEquityComponents

us-gaap:PaymentsToAcquireMarketableSecurities

us-gaap:ProceedsFromIssuanceOfCommonStock
us-gaap:BalanceSheetLocation, us-gaap:TypeOfArrangement
us-gaap:SubsidiarySaleOfStock
us-gaap:SubsidiarySaleOfStock, us-gaap:TypeOfArrangement
us-gaap:TypeOfArrangement

us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities

us-gaap:ProceedsFromStockOptionsExercised
us-gaap:CounterpartyName, us-gaap:SubsidiarySaleOfStock, us-gaap:TypeOfArrangement
us-gaap:SaleOfStockConsiderationReceivedOnTransaction
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
us-gaap:StatementEquityComponents
us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
us-gaap:CounterpartyName, us-gaap:StatementEquityComponents, us-gaap:SubsidiarySaleOfStock
us-gaap:StockIssuedDuringPeriodSharesNewIssues
us-gaap:CounterpartyName, us-gaap:SubsidiarySaleOfStock, us-gaap:TypeOfArrangement
us-gaap:StatementEquityComponents
us-gaap:StatementEquityComponents, us-gaap:SubsidiarySaleOfStock
us-gaap:SubsidiarySaleOfStock, us-gaap:TypeOfArrangement
us-gaap:TypeOfArrangement

us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
us-gaap:StatementEquityComponents

us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
us-gaap:StatementEquityComponents

us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
us-gaap:StatementEquityComponents

ntla:AccruedResearchAndDevelopmentExpensesCurrent
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement
us-gaap:AccountsReceivableNet
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement
us-gaap:AccountsReceivableRelatedParties

us-gaap:AccruedProfessionalFeesCurrent
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:AssetsFairValueDisclosure
us-gaap:FairValueByMeasurementFrequency

us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
us-gaap:FinancialInstrument

us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
us-gaap:FinancialInstrument

us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
us-gaap:FinancialInstrument

us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FinancialInstrument
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:CashAndCashEquivalentsFairValueDisclosure
us-gaap:FairValueByMeasurementFrequency

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
us-gaap:PlanName
us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
us-gaap:SubsidiarySaleOfStock, us-gaap:TypeOfArrangement

us-gaap:ContractWithCustomerLiability
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

us-gaap:ContractWithCustomerLiabilityNoncurrent

us-gaap:EmployeeRelatedLiabilitiesCurrent
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:InvestmentsFairValueDisclosure
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument
us-gaap:FairValueByMeasurementFrequency
us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument

us-gaap:MarketableSecuritiesCurrent

us-gaap:RestrictedCashEquivalents
us-gaap:CounterpartyName, us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByType
us-gaap:RevenueRemainingPerformanceObligation
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement
us-gaap:CounterpartyName, us-gaap:SubsidiarySaleOfStock, us-gaap:TypeOfArrangement
us-gaap:SaleOfStockPricePerShare
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
us-gaap:SubsidiarySaleOfStock, us-gaap:TypeOfArrangement
us-gaap:SharesIssuedPricePerShare
us-gaap:TypeOfArrangement

Tables

  2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
us-gaap:CommonStockValue █▄▄▄▄▄▄▁▁▁▁▁▁▁0.0060.0050.0050.0050.0050.0050.0050.0040.0040.0040.0040.0040.0040.004
 us-gaap:CommonStockParOrStatedValuePerShare us-gaap:CounterpartyName,us-gaap:SubsidiarySaleOfStock,us-gaap:TypeOfArrangement ntla:RegeneronPharmaceuticalsInc,us-gaap:PrivatePlacement,ntla:TwoThousandTwentyStockPurchaseAgreementNANANANANANANANANANANANANANA
 us-gaap:CommonStockParOrStatedValuePerShare us-gaap:CounterpartyName,us-gaap:TypeOfArrangement ntla:RegeneronPharmaceuticalsInc,ntla:TwoThousandTwentyStockPurchaseAgreementNANANANANANANANANANANANANANA
 us-gaap:CommonStockParOrStatedValuePerShare us-gaap:SubsidiarySaleOfStock,us-gaap:TypeOfArrangement ntla:FollowOnPublicOffering,ntla:UnderwritingAgreementNANANANANANANANANANANANANANA
us-gaap:CommonStockSharesIssued █▅▅▅▅▄▄▃▃▃▃▁▁▁58.72423850.60287550.19804448.87729747.71457545.47909845.2244843.36932343.18801243.09192242.38462336.08526636.06451736.025676
us-gaap:CommonStockSharesAuthorized ▄▄▄▄▄▄▄▄▄▄▄▄▄▄120.0120.0120.0120.0120.0120.0120.0120.0120.0120.0120.0120.0120.0120.0
us-gaap:CommonStockSharesOutstanding █▅▅▅▅▄▄▃▃▃▃▁▁▁58.72423850.60287550.19804448.87729747.71457545.47909845.2244843.36932343.18801243.09192242.38462336.08526636.06451736.025676
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted █▇▆▆▅▅▅▄▄▄▃▁▁▁53.36950.49149.3548.55445.81445.23432644.21543.16142.83642.04339.15535.18934.91634.723
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount █▁7.8297.491NANA5.3885.41NANANA5.171NANANA5.548
  2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax █▆▄▄▅▄▂▂▂▂▂▂▁▁16.26312.91610.93610.61611.11810.4337.887.4087.6777.4696.6687.3175.9176.215
us-gaap:CostsAndExpenses █▇▆▅▆▅▃▄▄▃▄▂▂▁49.29745.96440.70735.94438.57834.24228.62631.50731.27229.89931.38323.19221.93419.163
us-gaap:ResearchAndDevelopmentExpense █▇▆▅▄▄▃▄▄▄▃▂▂▁37.77134.6531.73127.51325.4623.70919.91823.23723.46722.49321.1717.48115.56513.431
us-gaap:GeneralAndAdministrativeExpense ▆▆▄▄█▆▄▃▃▃▅▁▂▁11.52611.3148.9768.43113.11810.5338.7088.277.8057.40610.2135.7116.3695.732
us-gaap:OperatingIncomeLoss ▁▁▂▄▃▄▅▄▄▅▄▇▇█-33.034-33.048-29.771-25.328-27.46-23.809-20.746-24.099-23.595-22.43-24.715-15.875-16.017-12.948
us-gaap:AllocatedShareBasedCompensationExpense ▅▄▂▂▄▄▃▄▅▄█▂▁▁4.7644.1573.0163.0794.4044.5923.5824.4564.9014.1076.5963.2472.8492.63
us-gaap:ProfitLoss ▁▁▃▅▄▅▆▅▅▆▄█-32.393-31.806-28.276-23.634-25.683-21.94-19.066-22.702-22.219-21.356-23.963-15.356NANA
us-gaap:NetIncomeLoss ▁▁▂▄▃▅▆▄▅▅▄▇▇█-32.393-31.806-28.276-23.634-25.683-21.94-19.066-22.702-22.219-21.356-23.963-15.356-15.593-12.631
 us-gaap:NetIncomeLoss us-gaap:StatementEquityComponents us-gaap:RetainedEarnings▁█-32.393-31.806NA-23.634-25.683-21.94NA-22.702-22.219-21.356NANANANA
us-gaap:ComprehensiveIncomeNetOfTax ▁▁▃▆▅▇█▆▆▇-32.611-31.694-28.351-23.553-25.487-21.853-19.094-22.702-22.219-21.356NANANANA
  2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
  2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
  2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
us-gaap:Assets █▃▃▄▄▄▄▃▄▄▅▁▁▂490.83314.752334.28346.635352.441344.363347.315321.233339.778359.545376.235249.17264.975279.263
us-gaap:LiabilitiesAndStockholdersEquity █▃▃▄▄▄▄▃▄▄▅▁▁▂490.83314.752334.28346.635352.441344.363347.315321.233339.778359.545376.235249.17264.975279.263
us-gaap:StockholdersEquity █▄▅▅▅▅▅▄▅▆▆▁▁▂351.587247.759269.881275.652276.866264.338277.92263.27279.336295.499300.597175.847187.585199.883
  2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
us-gaap:AssetsCurrent █▂▃▃▄▃▄▃▄▅▅▁▂▂446.367269.76289.481295.935307.137303.693324.977298.829317.629337.72354.83229.053245.919261.078
us-gaap:CashAndCashEquivalentsAtCarryingValue █▂▁▁▁▁▁▇▇▇█▅▅▆361.68780.99357.22638.4449.1447.09758.856293.248305.538327.778340.678222.264241.047257.551
us-gaap:AccountsReceivableNetCurrent ▂█▂▂▂▂▄▁▅▄▆▂▁▁3.86413.3684.623.5994.1883.5917.5472.8138.6097.46610.4714.4932.7642.443
us-gaap:PrepaidExpenseAndOtherAssetsCurrent ▇█▆█▆▄▄▃▄▃▄▃▂▁5.6996.1335.1356.4144.713.523.3712.7683.4822.4763.6812.2962.1081.084
  2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
us-gaap:PropertyPlantAndEquipmentNet ▆▇█▇▇▇▇▇▆▆▅▃▂▁16.40217.25117.99617.20616.69416.66917.06116.93516.5816.0115.27213.5612.57811.418
us-gaap:OperatingLeaseRightOfUseAsset ▆█▁▃▃▃23.46924.91819.13720.66320.92321.012NANANANANANANANA
us-gaap:OtherAssetsNoncurrent ▄▁▁▁▁▁▅▆▆▆▇█▇█4.5922.8232.922.9632.9482.9895.2775.4695.5695.8156.1336.5576.4786.767
  2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
us-gaap:LiabilitiesCurrent █▃▃▄▄▄▄▁▁▁▂▁▁▁59.14235.30435.63337.51938.46339.23440.57225.91525.16925.58331.35925.78626.37124.91
us-gaap:AccountsPayableCurrent ▁▇▇█▄▇▅▄▂▄▄▄▄▃0.0073.873.9414.5481.8483.6872.7081.7540.3351.9162.1722.1942.2671.434
us-gaap:OtherAccruedLiabilitiesCurrent ▁▇█▃▃▂▁0.6451.0711.1910.770.7730.7280.606NANANA0.679NANANA
us-gaap:AccruedLiabilitiesCurrent █▇▇▆▆▃▅▅▄▃▄▂▂▁15.37413.10213.27311.64411.8987.73510.7429.8939.1566.6057.9995.9395.3123.559
us-gaap:OperatingLeaseLiabilityCurrent █▁▄5.8345.6935.745NANANANANANANANANANANA
us-gaap:ContractWithCustomerLiabilityCurrent █▁▁▂▃▄▅▁37.92712.63912.67415.82219.65223.43127.12214.268NANA21.188NANANA
  2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
us-gaap:OperatingLeaseLiabilityNoncurrent ▆█▁17.34918.66912.63NANANANANANANANANANANA
  2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
us-gaap:StockholdersEquity █▄▅▅▅▅▅▄▅▆▆▁▁▂351.587247.759269.881275.652276.866264.338277.92263.27279.336295.499300.597175.847187.585199.883
us-gaap:CommonStockValue █▄▄▄▄▄▄▁▁▁▁▁▁▁0.0060.0050.0050.0050.0050.0050.0050.0040.0040.0040.0040.0040.0040.004
us-gaap:AdditionalPaidInCapitalCommonStock █▆▆▅▅▄▄▄▄▄▃▁▁▁716.503580.065570.493547.913525.574487.559478.968445.225438.589432.533421.706272.993269.375266.08
us-gaap:RetainedEarningsAccumulatedDeficit ▁▂▃▃▄▄▅▅▆▆▇▇██-365.077-332.684-300.878-272.602-248.968-223.285-201.025-181.959-159.257-137.038-121.113-97.15-81.794-66.201
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax ▄█▆▇▆▃▁0.1550.3730.2610.3360.2550.059-0.028NANANANANANANA
us-gaap:StockIssuedDuringPeriodValueNewIssues NA5.079NA19.06831.4133.639NANANANANANANANA
 us-gaap:StockIssuedDuringPeriodValueNewIssues us-gaap:CounterpartyName,us-gaap:StatementEquityComponents,us-gaap:SubsidiarySaleOfStock ntla:RegeneronPharmaceuticalsInc,us-gaap:AdditionalPaidInCapital,us-gaap:PrivatePlacement12.58NANANANANANANANANANANANANA
 us-gaap:StockIssuedDuringPeriodValueNewIssues us-gaap:CounterpartyName,us-gaap:SubsidiarySaleOfStock ntla:RegeneronPharmaceuticalsInc,us-gaap:PrivatePlacement12.58NANANANANANANANANANANANANA
 us-gaap:StockIssuedDuringPeriodValueNewIssues us-gaap:CounterpartyName,us-gaap:SubsidiarySaleOfStock,us-gaap:TypeOfArrangement ntla:RegeneronPharmaceuticalsInc,us-gaap:PrivatePlacement,ntla:TwoThousandTwentyStockPurchaseAgreementNANANANANANANANANANANANANANA
 us-gaap:StockIssuedDuringPeriodValueNewIssues us-gaap:StatementEquityComponents us-gaap:AdditionalPaidInCapitalNA5.079NA19.06831.4133.639NANANANANANANANA
 us-gaap:StockIssuedDuringPeriodValueNewIssues us-gaap:StatementEquityComponents,us-gaap:SubsidiarySaleOfStock us-gaap:AdditionalPaidInCapital,ntla:AtMarketOffering█▁9.6435.079NANA31.4133.639NANANANANANANANA
 us-gaap:StockIssuedDuringPeriodValueNewIssues us-gaap:StatementEquityComponents,us-gaap:SubsidiarySaleOfStock us-gaap:AdditionalPaidInCapital,ntla:FollowOnPublicOffering107.731NANANANANANANANANANANANANA
 us-gaap:StockIssuedDuringPeriodValueNewIssues us-gaap:StatementEquityComponents,us-gaap:SubsidiarySaleOfStock us-gaap:CommonStock,ntla:FollowOnPublicOffering0.001NANANANANANANANANANANANANA
 us-gaap:StockIssuedDuringPeriodValueNewIssues us-gaap:SubsidiarySaleOfStock ntla:AtMarketOffering█▁9.6435.079NANA31.4133.639NANANANANANANANA
 us-gaap:StockIssuedDuringPeriodValueNewIssues us-gaap:SubsidiarySaleOfStock ntla:FollowOnPublicOffering107.732NANANANANANANANANANANANANA
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue █▁4.7644.157NA3.0794.4044.592NA4.4564.9014.107NANANANA
  2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
us-gaap:NetCashProvidedByUsedInOperatingActivities █▁▂▂▂▂▃▃▂▃▂▃57.417-38.545-28.662-25.448-27.677-21.453-8.538-12.454-22.495-17.77-21.306-16.894NANA
us-gaap:NetCashProvidedByUsedInInvestingActivities █▇▇▆▇▆▁▆▆▆▆▆92.96357.44827.884-31.65223.2495.695-256.016-2.016-0.9-1.85-2.397-2.26NANA
us-gaap:NetCashProvidedByUsedInFinancingActivities █▁▂▃▁▁▂▁▁▁█▁132.2254.86419.56446.46.4713.99930.1622.181.1556.72142.1170.371NANA
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect █▄▄▄▄▄▁▄282.60523.76718.786-10.72.043-11.759-234.392-12.29NANANANANANA
  2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
us-gaap:NetCashProvidedByUsedInOperatingActivities █▁▂▂▂▂▃▃▂▃▂▃57.417-38.545-28.662-25.448-27.677-21.453-8.538-12.454-22.495-17.77-21.306-16.894NANA
us-gaap:NetIncomeLoss ▁▁▂▄▃▅▆▄▅▅▄▇▇█-32.393-31.806-28.276-23.634-25.683-21.94-19.066-22.702-22.219-21.356-23.963-15.356-15.593-12.631
 us-gaap:NetIncomeLoss us-gaap:StatementEquityComponents us-gaap:RetainedEarnings▁█-32.393-31.806NA-23.634-25.683-21.94NA-22.702-22.219-21.356NANANANA
us-gaap:ProfitLoss ▁▁▃▅▄▅▆▅▅▆▄█-32.393-31.806-28.276-23.634-25.683-21.94-19.066-22.702-22.219-21.356-23.963-15.356NANA
us-gaap:DepreciationDepletionAndAmortization ███▆▆▆▅▅▄▄▂▂▁▁1.5661.5411.5831.3831.3221.2991.2271.1521.0731.0120.8330.790.7110.66
us-gaap:IncreaseDecreaseInAccountsReceivable ▁█▅▄▅▃▆▂▅▃▇▅▅▃-9.5048.7481.021-0.5890.597-3.9564.734-5.7961.143-3.0055.9781.7290.321-4.011
us-gaap:ShareBasedCompensation ▅▄▂▂▄▄▃▄▅▄█▂▁▁4.7644.1573.0163.0794.4044.5923.5824.4564.9014.1076.5963.2472.8492.63
  2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
us-gaap:NetCashProvidedByUsedInInvestingActivities █▇▇▆▇▆▁▆▆▆▆▆92.96357.44827.884-31.65223.2495.695-256.016-2.016-0.9-1.85-2.397-2.26NANA
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment ▁▁▅▃▁▂▃▃▁▃▄▄▂█1.0360.8452.5721.7480.9411.5331.5922.0160.91.852.3972.261.2724.162
  2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
us-gaap:NetCashProvidedByUsedInFinancingActivities █▁▂▃▁▁▂▁▁▁█▁132.2254.86419.56446.46.4713.99930.1622.181.1556.72142.1170.371NANA
  2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31

None

us-gaap:CommonStockValue

us-gaap:CommonStockValue


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-03-312015-12-31
Value6000.05000.05000.05000.05000.05000.05000.04000.04000.04000.04000.04000.04000.04000.04000.000
Percentage of CommonStockValue100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.00.0
Percentage of Assets0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

None

us-gaap:CommonStockParOrStatedValuePerShare us-gaap:CounterpartyName, us-gaap:SubsidiarySaleOfStock, us-gaap:TypeOfArrangement

us-gaap:CommonStockParOrStatedValuePerShare

ntla:RegeneronPharmaceuticalsInc, us-gaap:PrivatePlacement, ntla:TwoThousandTwentyStockPurchaseAgreement


None
Period End2020-05-31
Value0.0001
Percentage of CommonStockParOrStatedValuePerShare100.0

us-gaap:CommonStockParOrStatedValuePerShare us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

ntla:RegeneronPharmaceuticalsInc, ntla:TwoThousandTwentyStockPurchaseAgreement


None
Period End2020-05-30
Value0.0001
Percentage of CommonStockParOrStatedValuePerShare0.0

us-gaap:CommonStockParOrStatedValuePerShare us-gaap:SubsidiarySaleOfStock, us-gaap:TypeOfArrangement

ntla:FollowOnPublicOffering, ntla:UnderwritingAgreement


None
Period End2020-06-01
Value0.0001
Percentage of CommonStockParOrStatedValuePerShare0.0

None

us-gaap:CommonStockSharesIssued

us-gaap:CommonStockSharesIssued


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
Value58505048474545434343423636363635352.5587552.558755
Percentage of CommonStockSharesIssued100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

None

us-gaap:CommonStockSharesAuthorized

us-gaap:CommonStockSharesAuthorized


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
Value1201201201201201201201201201201201201201201201201205050
Percentage of CommonStockSharesAuthorized100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

None

us-gaap:CommonStockSharesOutstanding

us-gaap:CommonStockSharesOutstanding


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
Value58505048474545434343423636363635352.5587552.558755
Percentage of CommonStockSharesOutstanding100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:CommonStockSharesOutstanding us-gaap:StatementEquityComponents

us-gaap:CommonStock


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312016-12-312016-09-302016-06-302015-12-31
Value58505048474545434343423635352.558755
Percentage of CommonStockSharesOutstanding100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

None

us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted

us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-31
Value53504948454544434242393534343434190.6760.5480.2941.2841.284
Percentage of WeightedAverageNumberOfShareOutstandingBasicAndDiluted100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

None

us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount


None
Period End2020-06-302020-03-312019-06-302019-03-312018-03-312017-03-312016-09-302016-06-302016-03-312015-09-302015-06-302015-03-31
Value7.8297.4915.3885.415.1715.5484.584.74.392252423
Percentage of AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecurities

us-gaap:EmployeeStockOption


None
Period End2020-06-302020-03-312019-06-302019-03-312018-03-312017-03-312016-09-302016-06-302016-03-312015-09-30
Value7.5817.2435.3155.3314.7714.3733.0292.9352.6180.272
Percentage of AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount96.896.798.698.592.378.866.162.459.61.1

us-gaap:RestrictedStockUnitsRSU


None
Period End2020-06-302020-03-312019-06-302019-03-312018-03-312017-03-312016-09-302016-06-302016-03-312015-09-30
Value0.2480.2480.0730.0790.41.1751.5511.7651.7742.121
Percentage of AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount3.23.31.41.57.721.233.937.640.48.2

us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount us-gaap:AwardType

ntla:PerformanceBasedStockOptions


None
Period End2020-03-312019-03-31
Value0.173750.18875
Percentage of AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount2.33.5

None

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value1612101011107.887.4087.6777.4696.6687.3175.9176.215
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement

ntla:RegeneronPharmaceuticalsInc, ntla:ResearchAndDevelopmentServices, ntla:RegeneronArrangement


None
Period End2020-06-302020-03-312019-12-312019-09-30
Value3.84.73.62.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax23.436.432.924.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax23.436.432.924.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax ntla:RegeneronPharmaceuticalsInc ntla:ResearchAndDevelopmentServices ntla:RegeneronArrangement100.0100.0100.0100.0

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

ntla:NovartisInstitutesForBioMedicalResearchInc, ntla:NovartisArrangement


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302017-12-312017-09-302017-06-30
Value0.05.04.24.84.84.73.12.42.42.52.42.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.038.738.445.243.245.039.332.431.337.532.838.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.038.738.445.243.245.039.332.431.337.532.838.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax ntla:NovartisInstitutesForBioMedicalResearchInc ntla:NovartisArrangement0.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

ntla:NovartisInstitutesForBioMedicalResearchInc, ntla:RegeneronArrangement


None
Period End2020-06-302020-03-31
Value0.05.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.038.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.038.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax ntla:NovartisInstitutesForBioMedicalResearchInc ntla:RegeneronArrangement0.0100.0

ntla:RegeneronPharmaceuticalsInc, ntla:RegeneronArrangement


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value167.96.85.86.35.74.75.05.35.14.24.93.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax100.261.262.254.656.754.659.667.569.068.363.067.060.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax100.261.262.254.656.754.659.667.569.068.363.067.060.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax ntla:RegeneronPharmaceuticalsInc ntla:RegeneronArrangement100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

None

us-gaap:CostsAndExpenses

us-gaap:CostsAndExpenses


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-31
Value49454035383428313129312321191612118.4717.1844.9894.7992.481
Percentage of CostsAndExpenses100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax303.1355.9372.2338.6347.0328.2363.3425.3407.3400.3470.7317.0370.7308.30.00.00.00.00.00.00.00.0

None

us-gaap:ResearchAndDevelopmentExpense

us-gaap:ResearchAndDevelopmentExpense


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-31
Value3734312725231923232221171513117.8617.4235.2254.3753.4581.9661.371
Percentage of ResearchAndDevelopmentExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax232.3268.3290.2259.2229.0227.3252.8313.7305.7301.2317.5238.9263.1216.10.00.00.00.00.00.00.00.0

None

us-gaap:GeneralAndAdministrativeExpense

us-gaap:GeneralAndAdministrativeExpense


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-31
Value11118.9768.43113108.7088.277.8057.406105.7116.3695.7325.1184.7053.7293.2462.8091.5312.8331.11
Percentage of GeneralAndAdministrativeExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax70.987.682.179.4118.0101.0110.5111.6101.799.2153.278.1107.692.20.00.00.00.00.00.00.00.0

None

us-gaap:OperatingIncomeLoss

us-gaap:OperatingIncomeLoss


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-31
Value-33034000.0-33048000.0-29771000.0-25328000.0-27460000.0-23809000.0-20746000.0-24099000.0-23595000.0-22430000.0-24715000.0-15875000.0-16017000.0-12948000.0-10822000.0-7697000.0-6946000.0-6694000.0-5491000.0-3301000.0-3422000.0-1195000.0
Percentage of OperatingIncomeLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-203.1-255.9-272.2-238.6-247.0-228.2-263.3-325.3-307.3-300.3-370.7-217.0-270.7-208.30.00.00.00.00.00.00.00.0

None

us-gaap:AllocatedShareBasedCompensationExpense

us-gaap:AllocatedShareBasedCompensationExpense


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-30
Value4.7644.1573.0163.0794.4044.5923.5824.4564.9014.1076.5963.2472.8492.632.0152.0551.833
Percentage of AllocatedShareBasedCompensationExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax29.332.227.629.039.644.045.560.263.855.098.944.448.142.30.00.00.0

us-gaap:AllocatedShareBasedCompensationExpense us-gaap:IncomeStatementLocation

us-gaap:GeneralAndAdministrativeExpense


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-30
Value2.3741.9971.4221.5662.3082.8092.2051.8652.2681.7144.3641.261.2911.1270.8580.820.596
Percentage of AllocatedShareBasedCompensationExpense49.848.047.150.952.461.261.641.946.341.766.238.845.342.942.639.932.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax14.615.513.014.820.826.928.025.229.522.965.417.221.818.10.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:GeneralAndAdministrativeExpense0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:ResearchAndDevelopmentExpense


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-30
Value2.392.161.5941.5132.0961.7831.3772.5912.6332.3932.2321.9871.5581.5031.1571.2351.237
Percentage of AllocatedShareBasedCompensationExpense50.252.052.949.147.638.838.458.153.758.333.861.254.757.157.460.167.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax14.716.714.614.318.917.117.535.034.332.033.527.226.324.20.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:ResearchAndDevelopmentExpense0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

None

us-gaap:ProfitLoss

us-gaap:ProfitLoss


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-30
Value-32393000.0-31806000.0-28276000.0-23634000.0-25683000.0-21940000.0-19066000.0-22702000.0-22219000.0-21356000.0-23963000.0-15356000.0
Percentage of ProfitLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-199.2-246.3-258.6-222.6-231.0-210.3-242.0-306.5-289.4-285.9-359.4-209.9

None

us-gaap:NetIncomeLoss

us-gaap:NetIncomeLoss


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-31
Value-32393000.0-31806000.0-28276000.0-23634000.0-25683000.0-21940000.0-19066000.0-22702000.0-22219000.0-21356000.0-23963000.0-15356000.0-15593000.0-12631000.0-10563000.0-7482000.0-6900000.0-6689000.0-5245000.0-3019000.0-3040000.0-1093000.0
Percentage of NetIncomeLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-199.2-246.3-258.6-222.6-231.0-210.3-242.0-306.5-289.4-285.9-359.4-209.9-263.5-203.20.00.00.00.00.00.00.00.0

us-gaap:NetIncomeLoss us-gaap:StatementEquityComponents

us-gaap:RetainedEarnings


None
Period End2020-06-302020-03-312019-09-302019-06-302019-03-312018-09-302018-06-302018-03-312016-12-312016-09-30
Value-32393000.0-31806000.0-23634000.0-25683000.0-21940000.0-22702000.0-22219000.0-21356000.0-10563000.0-7482000.0
Percentage of NetIncomeLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-199.2-246.3-222.6-231.0-210.3-306.5-289.4-285.90.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:RetainedEarnings0.00.00.00.00.00.00.00.00.00.0

None

us-gaap:ComprehensiveIncomeNetOfTax

us-gaap:ComprehensiveIncomeNetOfTax


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
Value-32611000.0-31694000.0-28351000.0-23553000.0-25487000.0-21853000.0-19094000.0-22702000.0-22219000.0-21356000.0
Percentage of ComprehensiveIncomeNetOfTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-200.5-245.4-259.2-221.9-229.2-209.5-242.3-306.5-289.4-285.9

None

us-gaap:Assets

us-gaap:Assets


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
Value4903143343463523443473213393593762492642792983013107582
Percentage of Assets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

None

us-gaap:LiabilitiesAndStockholdersEquity

us-gaap:LiabilitiesAndStockholdersEquity


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
Value4903143343463523443473213393593762492642792983013107582
Percentage of LiabilitiesAndStockholdersEquity100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

None

us-gaap:StockholdersEquity

us-gaap:StockholdersEquity


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312014-12-312014-05-06
Value351247269275276264277263279295300175187199209218223-27.142-21.2017.5660.0
Percentage of StockholdersEquity100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.0
Percentage of Assets71.678.780.779.578.676.880.082.082.282.279.970.670.871.670.272.472.0-35.9-25.80.00.0

us-gaap:StockholdersEquity us-gaap:StatementEquityComponents

us-gaap:AccumulatedOtherComprehensiveIncome


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value0.1550.3730.2610.3360.2550.059-0.028
Percentage of StockholdersEquity0.00.20.10.10.10.0-0.0
Percentage of Assets0.00.10.10.10.10.0-0.0
Percentage of Assets us-gaap:AccumulatedOtherComprehensiveIncome0.00.00.00.00.00.00.0

us-gaap:AdditionalPaidInCapital


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312016-12-312016-09-302016-06-302015-12-31
Value7165805705475254874784454384324212632612590.735
Percentage of StockholdersEquity203.8234.1211.4198.8189.8184.4172.3169.1157.0146.4140.3125.5119.7115.9-3.5
Percentage of Assets146.0184.3170.7158.1149.1141.6137.9138.6129.1120.3112.188.186.683.40.9
Percentage of Assets us-gaap:AdditionalPaidInCapital0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:CommonStock


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312016-12-312016-09-302016-06-30
Value0.0060.0050.0050.0050.0050.0050.0050.0040.0040.0040.0040.0040.0040.004
Percentage of StockholdersEquity0.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Percentage of Assets0.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Percentage of Assets us-gaap:CommonStock0.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:RetainedEarnings


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312016-12-312016-09-302016-06-302015-12-312014-12-31
Value-365.077-332.684-300.878-272.602-248.968-223.285-201.025-181.959-159.257-137.038-121.113-53.57-43.007-35.525-21.936-9.539
Percentage of StockholdersEquity-103.8-134.3-111.5-98.9-89.9-84.5-72.3-69.1-57.0-46.4-40.3-25.5-19.7-15.9103.5-126.1
Percentage of Assets-74.4-105.7-90.0-78.6-70.6-64.8-57.9-56.6-46.9-38.1-32.2-17.9-14.3-11.4-26.70.0
Percentage of Assets us-gaap:RetainedEarnings0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

None

us-gaap:AssetsCurrent

us-gaap:AssetsCurrent


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
Value4462692892953073033242983173373542292452612812923026577
Percentage of AssetsCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets90.985.786.685.487.188.293.693.093.593.994.391.992.893.594.197.197.587.394.5

None

us-gaap:CashAndCashEquivalentsAtCarryingValue

us-gaap:CashAndCashEquivalentsAtCarryingValue


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-31
Value36180573849475829330532734022224125727329030064758219189.845
Percentage of CashAndCashEquivalentsAtCarryingValue100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets73.725.717.111.113.913.716.991.389.991.290.589.291.092.291.396.496.885.092.30.00.00.00.0

None

us-gaap:AccountsReceivableNetCurrent

us-gaap:AccountsReceivableNetCurrent


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
Value3.864134.623.5994.1883.5917.5472.8138.6097.466104.4932.7642.4436.4541.1121.01.01.0
Percentage of AccountsReceivableNetCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.84.21.41.01.21.02.20.92.52.12.81.81.00.92.20.40.31.31.2

None

us-gaap:PrepaidExpenseAndOtherAssetsCurrent

us-gaap:PrepaidExpenseAndOtherAssetsCurrent


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
Value5699000.06133000.05135000.06414000.04710000.03520000.03371000.02768000.03482000.02476000.03681000.02296000.02108000.01084000.01788000.0972000.01217000.0745000.0810000.0
Percentage of PrepaidExpenseAndOtherAssetsCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets1.21.91.51.91.31.01.00.91.00.71.00.90.80.40.60.30.41.01.0

None

us-gaap:PropertyPlantAndEquipmentNet

us-gaap:PropertyPlantAndEquipmentNet


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
Value1617171716161716161615131211105.4924.4214.2282.708
Percentage of PropertyPlantAndEquipmentNet100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets3.35.55.45.04.74.84.95.34.94.54.15.44.74.13.61.81.45.63.3

None

us-gaap:OperatingLeaseRightOfUseAsset

us-gaap:OperatingLeaseRightOfUseAsset


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
Value232419202021
Percentage of OperatingLeaseRightOfUseAsset100.0100.0100.0100.0100.0100.0
Percentage of Assets4.87.95.76.05.96.1

None

us-gaap:OtherAssetsNoncurrent

us-gaap:OtherAssetsNoncurrent


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
Value4592000.02823000.02920000.02963000.02948000.02989000.05277000.05469000.05569000.05815000.06133000.06557000.06478000.06767000.07035000.03275000.03299000.05375000.01805000.0
Percentage of OtherAssetsNoncurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.90.90.90.90.80.91.51.71.61.61.62.62.42.42.41.11.17.12.2

None

us-gaap:LiabilitiesCurrent

us-gaap:LiabilitiesCurrent


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
Value59353537383940252525312526243022211010
Percentage of LiabilitiesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets12.011.210.710.810.911.411.78.17.47.18.310.310.08.910.37.57.014.513.0

None

us-gaap:AccountsPayableCurrent

us-gaap:AccountsPayableCurrent


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
Value7000.03870000.03941000.04548000.01848000.03687000.02708000.01754000.0335000.01916000.02172000.02194000.02267000.01434000.04652000.0657000.01042000.01206000.01360000.0
Percentage of AccountsPayableCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.01.21.21.30.51.10.80.50.10.50.60.90.90.51.60.20.31.61.7

None

us-gaap:OtherAccruedLiabilitiesCurrent

us-gaap:OtherAccruedLiabilitiesCurrent


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312017-12-312016-03-312015-12-31
Value645000.01071000.01191000.0770000.0773000.0728000.0606000.0679000.0400000.0600000.0
Percentage of OtherAccruedLiabilitiesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.10.30.40.20.20.20.20.20.50.7

None

us-gaap:AccruedLiabilitiesCurrent

us-gaap:AccruedLiabilitiesCurrent


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
Value15131311117.735109.8939.1566.6057.9995.9395.3123.5595.94.814.2882.9732.788
Percentage of AccruedLiabilitiesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets3.14.24.03.43.42.23.13.12.71.82.12.42.01.32.01.61.43.93.4

None

us-gaap:OperatingLeaseLiabilityCurrent

us-gaap:OperatingLeaseLiabilityCurrent


None
Period End2020-06-302020-03-312019-12-31
Value5834000.05693000.05745000.0
Percentage of OperatingLeaseLiabilityCurrent100.0100.0100.0
Percentage of Assets1.21.81.7

None

us-gaap:ContractWithCustomerLiabilityCurrent

us-gaap:ContractWithCustomerLiabilityCurrent


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302017-12-31
Value371212151923271421
Percentage of ContractWithCustomerLiabilityCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets7.74.03.84.65.66.87.84.45.6

None

us-gaap:OperatingLeaseLiabilityNoncurrent

us-gaap:OperatingLeaseLiabilityNoncurrent


None
Period End2020-06-302020-03-312019-12-31
Value171812
Percentage of OperatingLeaseLiabilityNoncurrent100.0100.0100.0
Percentage of Assets3.55.93.8

None

us-gaap:StockholdersEquity

us-gaap:StockholdersEquity


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312014-12-312014-05-06
Value351247269275276264277263279295300175187199209218223-27.142-21.2017.5660.0
Percentage of StockholdersEquity100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.0
Percentage of Assets71.678.780.779.578.676.880.082.082.282.279.970.670.871.670.272.472.0-35.9-25.80.00.0

us-gaap:StockholdersEquity us-gaap:StatementEquityComponents

us-gaap:AccumulatedOtherComprehensiveIncome


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value0.1550.3730.2610.3360.2550.059-0.028
Percentage of StockholdersEquity0.00.20.10.10.10.0-0.0
Percentage of Assets0.00.10.10.10.10.0-0.0
Percentage of Assets us-gaap:AccumulatedOtherComprehensiveIncome0.00.00.00.00.00.00.0

us-gaap:AdditionalPaidInCapital


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312016-12-312016-09-302016-06-302015-12-31
Value7165805705475254874784454384324212632612590.735
Percentage of StockholdersEquity203.8234.1211.4198.8189.8184.4172.3169.1157.0146.4140.3125.5119.7115.9-3.5
Percentage of Assets146.0184.3170.7158.1149.1141.6137.9138.6129.1120.3112.188.186.683.40.9
Percentage of Assets us-gaap:AdditionalPaidInCapital0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:CommonStock


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312016-12-312016-09-302016-06-30
Value0.0060.0050.0050.0050.0050.0050.0050.0040.0040.0040.0040.0040.0040.004
Percentage of StockholdersEquity0.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Percentage of Assets0.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Percentage of Assets us-gaap:CommonStock0.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:RetainedEarnings


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312016-12-312016-09-302016-06-302015-12-312014-12-31
Value-365.077-332.684-300.878-272.602-248.968-223.285-201.025-181.959-159.257-137.038-121.113-53.57-43.007-35.525-21.936-9.539
Percentage of StockholdersEquity-103.8-134.3-111.5-98.9-89.9-84.5-72.3-69.1-57.0-46.4-40.3-25.5-19.7-15.9103.5-126.1
Percentage of Assets-74.4-105.7-90.0-78.6-70.6-64.8-57.9-56.6-46.9-38.1-32.2-17.9-14.3-11.4-26.70.0
Percentage of Assets us-gaap:RetainedEarnings0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

None

us-gaap:CommonStockValue

us-gaap:CommonStockValue


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-03-312015-12-31
Value6000.05000.05000.05000.05000.05000.05000.04000.04000.04000.04000.04000.04000.04000.04000.000
Percentage of CommonStockValue100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.00.0
Percentage of Assets0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

None

us-gaap:AdditionalPaidInCapitalCommonStock

us-gaap:AdditionalPaidInCapitalCommonStock


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
Value7165805705475254874784454384324212722692662632612591.4830.735
Percentage of AdditionalPaidInCapitalCommonStock100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets146.0184.3170.7158.1149.1141.6137.9138.6129.1120.3112.1109.6101.795.388.186.683.42.00.9

None

us-gaap:RetainedEarningsAccumulatedDeficit

us-gaap:RetainedEarningsAccumulatedDeficit


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
Value-365080000.0-332680000.0-300880000.0-272600000.0-248970000.0-223280000.0-201020000.0-181960000.0-159260000.0-137040000.0-121110000.0-97150000.0-81794000.0-66201000.0-53570000.0-43007000.0-35525000.0-28625000.0-21936000.0
Percentage of RetainedEarningsAccumulatedDeficit100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets-74.4-105.7-90.0-78.6-70.6-64.8-57.9-56.6-46.9-38.1-32.2-39.0-30.9-23.7-17.9-14.3-11.4-37.9-26.7

None

us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax

us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value155000.0373000.0261000.0336000.0255000.059000.0-28000.0
Percentage of AccumulatedOtherComprehensiveIncomeLossNetOfTax100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.00.10.10.10.10.0-0.0

None

us-gaap:StockIssuedDuringPeriodValueNewIssues

us-gaap:StockIssuedDuringPeriodValueNewIssues


None
Period End2020-03-312019-09-302019-06-302019-03-312016-12-312016-09-30
Value5.07919313.6390.0-0.051
Percentage of StockIssuedDuringPeriodValueNewIssues100.0100.0100.0100.00.0100.0
Percentage of Assets0.00.00.00.00.00.0

us-gaap:StockIssuedDuringPeriodValueNewIssues us-gaap:CounterpartyName, us-gaap:StatementEquityComponents, us-gaap:SubsidiarySaleOfStock

ntla:RegeneronPharmaceuticalsInc, us-gaap:AdditionalPaidInCapital, us-gaap:PrivatePlacement


None
Period End2020-06-30
Value12
Percentage of StockIssuedDuringPeriodValueNewIssues0.0
Percentage of Assets0.0
Percentage of Assets ntla:RegeneronPharmaceuticalsInc us-gaap:AdditionalPaidInCapital us-gaap:PrivatePlacement0.0

us-gaap:StockIssuedDuringPeriodValueNewIssues us-gaap:CounterpartyName, us-gaap:SubsidiarySaleOfStock

ntla:RegeneronPharmaceuticalsInc, us-gaap:PrivatePlacement


None
Period End2020-06-30
Value12
Percentage of StockIssuedDuringPeriodValueNewIssues0.0
Percentage of Assets0.0
Percentage of Assets ntla:RegeneronPharmaceuticalsInc us-gaap:PrivatePlacement0.0

us-gaap:StockIssuedDuringPeriodValueNewIssues us-gaap:CounterpartyName, us-gaap:SubsidiarySaleOfStock, us-gaap:TypeOfArrangement

ntla:RegeneronPharmaceuticalsInc, us-gaap:PrivatePlacement, ntla:TwoThousandTwentyStockPurchaseAgreement


None
Period End2020-05-31
Value12
Percentage of StockIssuedDuringPeriodValueNewIssues0.0
Percentage of Assets0.0
Percentage of Assets ntla:RegeneronPharmaceuticalsInc us-gaap:PrivatePlacement ntla:TwoThousandTwentyStockPurchaseAgreement0.0

us-gaap:StockIssuedDuringPeriodValueNewIssues us-gaap:StatementEquityComponents

us-gaap:AdditionalPaidInCapital


None
Period End2020-03-312019-09-302019-06-302019-03-312016-12-312016-09-30
Value5.07919313.6390.0-0.051
Percentage of StockIssuedDuringPeriodValueNewIssues100.0100.0100.0100.00.0100.0
Percentage of Assets0.00.00.00.00.00.0
Percentage of Assets us-gaap:AdditionalPaidInCapital0.00.00.00.00.00.0

us-gaap:StockIssuedDuringPeriodValueNewIssues us-gaap:StatementEquityComponents, us-gaap:SubsidiarySaleOfStock

us-gaap:AdditionalPaidInCapital, ntla:AtMarketOffering


None
Period End2020-06-302020-03-312019-06-302019-03-31
Value9.6435.079313.639
Percentage of StockIssuedDuringPeriodValueNewIssues0.0100.0100.0100.0
Percentage of Assets0.00.00.00.0
Percentage of Assets us-gaap:AdditionalPaidInCapital ntla:AtMarketOffering0.00.00.00.0

us-gaap:AdditionalPaidInCapital, ntla:FollowOnPublicOffering


None
Period End2020-06-30
Value107
Percentage of StockIssuedDuringPeriodValueNewIssues0.0
Percentage of Assets0.0
Percentage of Assets us-gaap:AdditionalPaidInCapital ntla:FollowOnPublicOffering0.0

us-gaap:CommonStock, ntla:FollowOnPublicOffering


None
Period End2020-06-30
Value0.001
Percentage of StockIssuedDuringPeriodValueNewIssues0.0
Percentage of Assets0.0
Percentage of Assets us-gaap:CommonStock ntla:FollowOnPublicOffering0.0

us-gaap:StockIssuedDuringPeriodValueNewIssues us-gaap:SubsidiarySaleOfStock

ntla:AtMarketOffering


None
Period End2020-06-302020-03-312019-06-302019-03-31
Value9.6435.079313.639
Percentage of StockIssuedDuringPeriodValueNewIssues0.0100.0100.0100.0
Percentage of Assets0.00.00.00.0
Percentage of Assets ntla:AtMarketOffering0.00.00.00.0

ntla:FollowOnPublicOffering


None
Period End2020-06-30
Value107
Percentage of StockIssuedDuringPeriodValueNewIssues0.0
Percentage of Assets0.0
Percentage of Assets ntla:FollowOnPublicOffering0.0

None

us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue


None
Period End2020-06-302020-03-312019-09-302019-06-302019-03-312018-09-302018-06-302018-03-312016-12-312016-09-30
Value4.7644.1573.0794.4044.5924.4564.9014.1072.0152.055
Percentage of AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.00.00.00.00.00.00.00.00.00.0

us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue us-gaap:StatementEquityComponents

us-gaap:AdditionalPaidInCapital


None
Period End2020-06-302020-03-312019-09-302019-06-302019-03-312018-09-302018-06-302018-03-312016-12-312016-09-30
Value4.7644.1573.0794.4044.5924.4564.9014.1072.0152.055
Percentage of AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.00.00.00.00.00.00.00.00.00.0
Percentage of Assets us-gaap:AdditionalPaidInCapital0.00.00.00.00.00.00.00.00.00.0

None

us-gaap:NetCashProvidedByUsedInOperatingActivities

us-gaap:NetCashProvidedByUsedInOperatingActivities


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-30
Value57-38.545-28.662-25.448-27.677-21.453-8.538-12.454-22.495-17.77-21.306-16.894
Percentage of NetCashProvidedByUsedInOperatingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax353.1-298.4-262.1-239.7-248.9-205.6-108.4-168.1-293.0-237.9-319.5-230.9

None

us-gaap:NetCashProvidedByUsedInInvestingActivities

us-gaap:NetCashProvidedByUsedInInvestingActivities


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-30
Value925727-31.652235.695-256.016-2.016-0.9-1.85-2.397-2.26
Percentage of NetCashProvidedByUsedInInvestingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax571.6444.8255.0-298.2209.154.6-3248.9-27.2-11.7-24.8-35.9-30.9

None

us-gaap:NetCashProvidedByUsedInFinancingActivities

us-gaap:NetCashProvidedByUsedInFinancingActivities


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-30
Value1324.86419466.4713.999302.181.1556.721420.371
Percentage of NetCashProvidedByUsedInFinancingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax813.037.7178.9437.158.238.3382.829.415.090.02131.35.1

None

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value2822318-10.72.043-11.759-234.392-12.29
Percentage of CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1737.7184.0171.8-100.818.4-112.7-2974.5-165.9

None

us-gaap:NetCashProvidedByUsedInOperatingActivities

us-gaap:NetCashProvidedByUsedInOperatingActivities


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-30
Value57-38.545-28.662-25.448-27.677-21.453-8.538-12.454-22.495-17.77-21.306-16.894
Percentage of NetCashProvidedByUsedInOperatingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax353.1-298.4-262.1-239.7-248.9-205.6-108.4-168.1-293.0-237.9-319.5-230.9

None

us-gaap:NetIncomeLoss

us-gaap:NetIncomeLoss


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-31
Value-32393000.0-31806000.0-28276000.0-23634000.0-25683000.0-21940000.0-19066000.0-22702000.0-22219000.0-21356000.0-23963000.0-15356000.0-15593000.0-12631000.0-10563000.0-7482000.0-6900000.0-6689000.0-5245000.0-3019000.0-3040000.0-1093000.0
Percentage of NetIncomeLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-199.2-246.3-258.6-222.6-231.0-210.3-242.0-306.5-289.4-285.9-359.4-209.9-263.5-203.20.00.00.00.00.00.00.00.0

us-gaap:NetIncomeLoss us-gaap:StatementEquityComponents

us-gaap:RetainedEarnings


None
Period End2020-06-302020-03-312019-09-302019-06-302019-03-312018-09-302018-06-302018-03-312016-12-312016-09-30
Value-32393000.0-31806000.0-23634000.0-25683000.0-21940000.0-22702000.0-22219000.0-21356000.0-10563000.0-7482000.0
Percentage of NetIncomeLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-199.2-246.3-222.6-231.0-210.3-306.5-289.4-285.90.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:RetainedEarnings0.00.00.00.00.00.00.00.00.00.0

None

us-gaap:ProfitLoss

us-gaap:ProfitLoss


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-30
Value-32393000.0-31806000.0-28276000.0-23634000.0-25683000.0-21940000.0-19066000.0-22702000.0-22219000.0-21356000.0-23963000.0-15356000.0
Percentage of ProfitLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-199.2-246.3-258.6-222.6-231.0-210.3-242.0-306.5-289.4-285.9-359.4-209.9

None

us-gaap:DepreciationDepletionAndAmortization

us-gaap:DepreciationDepletionAndAmortization


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-30
Value1566000.01541000.01583000.01383000.01322000.01299000.01227000.01152000.01073000.01012000.0833000.0790000.0711000.0660000.0405000.0265000.0
Percentage of DepreciationDepletionAndAmortization100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

None

us-gaap:IncreaseDecreaseInAccountsReceivable

us-gaap:IncreaseDecreaseInAccountsReceivable


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
Value-9504000.08748000.01021000.0-589000.0597000.0-3956000.04734000.0-5796000.01143000.0-3005000.05978000.01729000.0321000.0-4011000.05342000.0
Percentage of IncreaseDecreaseInAccountsReceivable100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

None

us-gaap:ShareBasedCompensation

us-gaap:ShareBasedCompensation


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-31
Value4.7644.1573.0163.0794.4044.5923.5824.4564.9014.1076.5963.2472.8492.632.0152.0551.8330.8120.4630.5790.1510.115
Percentage of ShareBasedCompensation100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

None

us-gaap:NetCashProvidedByUsedInInvestingActivities

us-gaap:NetCashProvidedByUsedInInvestingActivities


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-30
Value925727-31.652235.695-256.016-2.016-0.9-1.85-2.397-2.26
Percentage of NetCashProvidedByUsedInInvestingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax571.6444.8255.0-298.2209.154.6-3248.9-27.2-11.7-24.8-35.9-30.9

None

us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

us-gaap:PaymentsToAcquirePropertyPlantAndEquipment


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-31
Value1.0360.8452.5721.7480.9411.5331.5922.0160.91.852.3972.261.2724.1623.4050.6051.1471.0080.8490.6020.5870.516
Percentage of PaymentsToAcquirePropertyPlantAndEquipment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

None

us-gaap:NetCashProvidedByUsedInFinancingActivities

us-gaap:NetCashProvidedByUsedInFinancingActivities


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-30
Value1324.86419466.4713.999302.181.1556.721420.371
Percentage of NetCashProvidedByUsedInFinancingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax813.037.7178.9437.158.238.3382.829.415.090.02131.35.1

None

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
Value7581000.07243100.05366000.05408300.05315500.05331500.05037700.04252500.04881000.04771300.04705400.04421200.04498900.04373200.03040200.03029000.02934700.02617900.0456370.0
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber us-gaap:AwardType

ntla:PerformanceBasedStockOptions


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
Value183750.0213750.0213750.0213750.0213750.0213750.0
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2.43.04.04.04.04.0

None

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
Value15.0315.0415.6715.5815.6115.4315.6315.214.9414.5212.0910.3410.149.998.358.357.946.696.04
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

None

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod


None
Period End2020-06-302020-03-31
Value0181020.0
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod0.0100.0

ntla:ContractWithCustomerLiabilityAdditions us-gaap:CounterpartyName, us-gaap:FinancialInstrument, us-gaap:TypeOfArrangement

ntla:ContractWithCustomerLiabilityAdditions

ntla:RegeneronPharmaceuticalsInc, ntla:OptionExercisedToIncreaseRegeneronTargetCap, ntla:TwoThousandAndTwentyRegeneronAmendment


None
Period End2020-05-30
Value30
Percentage of ContractWithCustomerLiabilityAdditions100.0

ntla:ContractWithCustomerLiabilityAdditions us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

ntla:NovartisInstitutesForBioMedicalResearchInc, ntla:NovartisArrangement


None
Period End2020-06-302020-03-312019-12-312019-09-302018-12-31
Value0.05.01.01.00.0
Percentage of ContractWithCustomerLiabilityAdditions0.00.00.00.00.0

ntla:RegeneronPharmaceuticalsInc, ntla:RegeneronArrangement


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value700.00.00.00.0750.0
Percentage of ContractWithCustomerLiabilityAdditions0.00.00.00.00.00.00.0

ntla:RegeneronPharmaceuticalsInc, ntla:TwoThousandAndTwentyRegeneronAmendment


None
Period End2020-05-30
Value70
Percentage of ContractWithCustomerLiabilityAdditions233.3

ntla:DecreaseInAccountsReceivables

ntla:DecreaseInAccountsReceivables


None
Period End2020-06-302020-03-312019-06-302019-03-31
Value1001.0173.5917.547
Percentage of DecreaseInAccountsReceivables100.0100.0100.0100.0

ntla:IncreaseDecreaseInOperatingLeaseLiabilities

ntla:IncreaseDecreaseInOperatingLeaseLiabilities


None
Period End2020-06-302020-03-312019-06-302019-03-31
Value-1359000.0-1360000.0155000.0-1081000.0
Percentage of IncreaseDecreaseInOperatingLeaseLiabilities100.0100.0100.0100.0

ntla:IncreaseDecreaseInOperatingRightOfUseAssets

ntla:IncreaseDecreaseInOperatingRightOfUseAssets


None
Period End2020-06-302020-03-312019-06-302019-03-31
Value-1629000.0-1566000.0-89000.0-1299000.0
Percentage of IncreaseDecreaseInOperatingRightOfUseAssets100.0100.0100.0100.0

ntla:IncreaseInAccountsReceivables

ntla:IncreaseInAccountsReceivables


None
Period End2020-06-302020-03-312019-06-302019-03-31
Value919.7654.1883.591
Percentage of IncreaseInAccountsReceivables100.0100.0100.0100.0

ntla:IncreaseInTargetCap us-gaap:CounterpartyName, us-gaap:Range, us-gaap:TypeOfArrangement

ntla:IncreaseInTargetCap

ntla:RegeneronPharmaceuticalsInc, srt:Maximum, ntla:TwoThousandAndTwentyRegeneronAmendment


None
Period End2020-05-30
Value15.0
Percentage of IncreaseInTargetCap100.0

ntla:RegeneronPharmaceuticalsInc, srt:Minimum, ntla:TwoThousandAndTwentyRegeneronAmendment


None
Period End2020-05-30
Value10.0
Percentage of IncreaseInTargetCap66.7

ntla:LegalAccountingAndOtherFees us-gaap:IncomeStatementLocation, us-gaap:TypeOfArrangement

ntla:LegalAccountingAndOtherFees

us-gaap:GeneralAndAdministrativeExpense, ntla:TwoThousandNineteenSalesAgreement


None
Period End2020-06-302020-03-312019-12-31
Value0100000.0100000.0
Percentage of LegalAccountingAndOtherFees0.0100.0100.0

ntla:PaymentOfRoyaltyPercentageOnNetProductSales us-gaap:CounterpartyName, us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByType, us-gaap:TypeOfArrangement

ntla:PaymentOfRoyaltyPercentageOnNetProductSales

ntla:RegeneronPharmaceuticalsInc, ntla:HemophiliaCoCoAgreements, ntla:TwoThousandAndTwentyRegeneronAmendment


None
Period End2020-05-30
Value0.65
Percentage of PaymentOfRoyaltyPercentageOnNetProductSales100.0

ntla:PaymentOfRoyaltyPercentageOnNetProductSales us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByType, us-gaap:TypeOfArrangement

ntla:HemophiliaCoCoAgreements, ntla:TwoThousandAndTwentyRegeneronAmendment


None
Period End2020-05-30
Value0.35
Percentage of PaymentOfRoyaltyPercentageOnNetProductSales53.8

ntla:PaymentsDueFromAffiliates us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

ntla:PaymentsDueFromAffiliates

ntla:RegeneronPharmaceuticalsInc, ntla:RegeneronArrangement


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-30
Value3.84.83.62.63.22.61.51.82.1
Percentage of PaymentsDueFromAffiliates100.0100.0100.0100.0100.0100.0100.0100.0100.0

ntla:PercentageOfGrossProceedsFromCommonStockAsSalesAgentCashCommission us-gaap:TypeOfArrangement

ntla:PercentageOfGrossProceedsFromCommonStockAsSalesAgentCashCommission

ntla:TwoThousandNineteenSalesAgreement


None
Period End2020-06-302020-03-312019-12-31
Value00.030
Percentage of PercentageOfGrossProceedsFromCommonStockAsSalesAgentCashCommission0.0100.00.0

ntla:PercentageOfPremiumOverVolumeWeightedAverageTradingPriceOfCommonStockDuring30DayPeriodPriorToClosingOfEquityTransaction us-gaap:CounterpartyName, us-gaap:SubsidiarySaleOfStock, us-gaap:TypeOfArrangement

ntla:PercentageOfPremiumOverVolumeWeightedAverageTradingPriceOfCommonStockDuring30DayPeriodPriorToClosingOfEquityTransaction

ntla:RegeneronPharmaceuticalsInc, us-gaap:PrivatePlacement, ntla:TwoThousandTwentyStockPurchaseAgreement


None
Period End2020-05-31
Value1.0
Percentage of PercentageOfPremiumOverVolumeWeightedAverageTradingPriceOfCommonStockDuring30DayPeriodPriorToClosingOfEquityTransaction100.0

ntla:PercentageOfPremiumOverVolumeWeightedAverageTradingPriceOfCommonStockDuring30DayPeriodPriorToClosingOfEquityTransaction us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

ntla:RegeneronPharmaceuticalsInc, ntla:TwoThousandTwentyStockPurchaseAgreement


None
Period End2020-05-30
Value1.0
Percentage of PercentageOfPremiumOverVolumeWeightedAverageTradingPriceOfCommonStockDuring30DayPeriodPriorToClosingOfEquityTransaction0.0

us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments

us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments


None
Period End2020-06-302020-03-312019-06-302019-03-31
Value68000.0200000.01208000.01422000.0
Percentage of AccretionAmortizationOfDiscountsAndPremiumsInvestments100.0100.0100.0100.0

us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts

us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts


None
Period End2020-03-312019-09-302019-06-302019-03-31
Value48000.0199000.03000.0120000.0
Percentage of AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts100.0100.0100.0100.0

us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts us-gaap:SubsidiarySaleOfStock

ntla:AtMarketOffering


None
Period End2020-06-302020-03-312019-06-302019-03-31
Value23000.048000.03000.0120000.0
Percentage of AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts0.0100.0100.0100.0

ntla:FollowOnPublicOffering


None
Period End2020-06-30
Value369000.0
Percentage of AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts0.0

us-gaap:CapitalExpendituresIncurredButNotYetPaid

us-gaap:CapitalExpendituresIncurredButNotYetPaid


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-31
Value-318000.0750000.0-216000.0149000.0421000.0446000.0149000.0-495000.0714000.0703000.0204000.0-439000.0662000.0378000.02146000.0731000.0-705000.0918000.075000.0-41000.0-122000.0307000.0
Percentage of CapitalExpendituresIncurredButNotYetPaid100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized

us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
Value-12457000.0-3151000.0-7334000.0-8016000.0-7930000.0-7842000.0-6332000.0-5595000.0-5535000.0-5474000.0
Percentage of ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:ContractWithCustomerLiabilityRevenueRecognized

us-gaap:ContractWithCustomerLiabilityRevenueRecognized


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
Value2.5233.1513.3348.0167.937.8426.3325.5955.5355.474
Percentage of ContractWithCustomerLiabilityRevenueRecognized100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:EarningsPerShareBasicAndDiluted

us-gaap:EarningsPerShareBasicAndDiluted


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-31
Value-0.61-0.63-0.57-0.49-0.56-0.49-0.43-0.53-0.52-0.51-0.61-0.44-0.45-0.36-0.31-0.22-0.36-9.89-9.57-10.27-2.37-0.85
Percentage of EarningsPerShareBasicAndDiluted100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:IncreaseDecreaseInAccountsPayable

us-gaap:IncreaseDecreaseInAccountsPayable


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-31
Value-3529000.0-370000.0-30000.02203000.0-1649000.01356000.0297000.01534000.0-1658000.059000.0-256000.0438000.0284000.0-954000.01630000.0521000.0-280000.0-87000.0-70000.0-792000.0837000.0360000.0
Percentage of IncreaseDecreaseInAccountsPayable100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:IncreaseDecreaseInAccruedLiabilities

us-gaap:IncreaseDecreaseInAccruedLiabilities


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-31
Value2257000.0177000.01267000.096000.03552000.0-2605000.01357000.01118000.01914000.0-1609000.02092000.0554000.01641000.0-1893000.01309000.0688000.01187000.0-134000.0-415000.0716000.01065000.0-561000.0
Percentage of IncreaseDecreaseInAccruedLiabilities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:IncreaseDecreaseInContractWithCustomerLiability

us-gaap:IncreaseDecreaseInContractWithCustomerLiability


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
Value75-3.151-6.334-7.016-6.93-6.8429.668-4.595-4.535-4.4740.31
Percentage of IncreaseDecreaseInContractWithCustomerLiability100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:IncreaseDecreaseInOtherOperatingAssets

us-gaap:IncreaseDecreaseInOtherOperatingAssets


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-30
Value-142000.0-97000.0-43000.015000.0-41000.0-84000.0-358000.0-100000.0-246000.0-318000.0-424000.079000.0-289000.0-268000.03760000.0-24000.0-124000.02823000.0-765000.0810000.0
Percentage of IncreaseDecreaseInOtherOperatingAssets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-31
Value116000.0448000.0-1280000.01704000.01189000.0150000.0603000.0-714000.01006000.0-1205000.01385000.0188000.01024000.0-704000.0817000.0-245000.0472000.0-65000.0165000.0123000.0169000.068000.0
Percentage of IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:InvestmentIncomeInterest

us-gaap:InvestmentIncomeInterest


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-31
Value641000.01242000.01495000.01694000.01777000.01869000.01680000.01397000.01376000.01074000.0752000.0519000.0424000.0317000.0259000.0215000.046000.05000.0
Percentage of InvestmentIncomeInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:MarketableSecuritiesUnrealizedGainLoss

us-gaap:MarketableSecuritiesUnrealizedGainLoss


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
Value-218000.0112000.0-75000.081000.0196000.087000.0
Percentage of MarketableSecuritiesUnrealizedGainLoss100.0100.0100.0100.0100.0100.0

us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent


None
Period End2020-06-302020-03-312019-09-302019-06-302019-03-31
Value-218000.0112000.081000.0196000.087000.0
Percentage of OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent100.0100.0100.0100.0100.0

us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent us-gaap:StatementEquityComponents

us-gaap:AccumulatedOtherComprehensiveIncome


None
Period End2020-06-302020-03-312019-09-302019-06-302019-03-31
Value-218000.0112000.081000.0196000.087000.0
Percentage of OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent100.0100.0100.0100.0100.0

us-gaap:PaymentsToAcquireMarketableSecurities

us-gaap:PaymentsToAcquireMarketableSecurities


None
Period End2020-06-302020-03-312019-06-302019-03-31
Value0.0013116319
Percentage of PaymentsToAcquireMarketableSecurities100.0100.0100.0100.0

us-gaap:ProceedsFromIssuanceOfCommonStock

us-gaap:ProceedsFromIssuanceOfCommonStock


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
Value2314.52818507.93.639
Percentage of ProceedsFromIssuanceOfCommonStock100.0100.0100.0100.0100.0100.0

us-gaap:ProceedsFromIssuanceOfCommonStock us-gaap:BalanceSheetLocation, us-gaap:TypeOfArrangement

ntla:CurrentAssets, ntla:TwoThousandNineteenSalesAgreement


None
Period End2020-03-31
Value0.5
Percentage of ProceedsFromIssuanceOfCommonStock11.0

us-gaap:ProceedsFromIssuanceOfCommonStock us-gaap:SubsidiarySaleOfStock

ntla:AtMarketOffering


None
Period End2020-06-302019-09-302019-06-30
Value9.7464.3
Percentage of ProceedsFromIssuanceOfCommonStock4.291.754.4

ntla:FollowOnPublicOffering


None
Period End2020-06-302019-09-302019-06-30
Value1080.00.0
Percentage of ProceedsFromIssuanceOfCommonStock46.80.00.0

us-gaap:ProceedsFromIssuanceOfCommonStock us-gaap:SubsidiarySaleOfStock, us-gaap:TypeOfArrangement

ntla:FollowOnPublicOffering, ntla:UnderwritingAgreement


None
Period End2020-06-05
Value107
Percentage of ProceedsFromIssuanceOfCommonStock0.0

us-gaap:ProceedsFromIssuanceOfCommonStock us-gaap:TypeOfArrangement

ntla:TwoThousandNineteenSalesAgreement


None
Period End2020-06-302020-03-31
Value9.65.1
Percentage of ProceedsFromIssuanceOfCommonStock4.2112.6

us-gaap:CollaborativeArrangement


None
Period End2020-06-302019-09-302019-06-30
Value1134.23.6
Percentage of ProceedsFromIssuanceOfCommonStock49.08.345.6

us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities

us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities


None
Period End2020-06-302020-03-312019-06-302019-03-31
Value948918726
Percentage of ProceedsFromSaleAndMaturityOfMarketableSecurities100.0100.0100.0100.0

us-gaap:ProceedsFromStockOptionsExercised

us-gaap:ProceedsFromStockOptionsExercised


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value1.0340.3360.870.1921.6640.361.1952.180.5576.720.6480.3710.090.047
Percentage of ProceedsFromStockOptionsExercised100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:SaleOfStockConsiderationReceivedOnTransaction us-gaap:CounterpartyName, us-gaap:SubsidiarySaleOfStock, us-gaap:TypeOfArrangement

us-gaap:SaleOfStockConsiderationReceivedOnTransaction

ntla:RegeneronPharmaceuticalsInc, us-gaap:PrivatePlacement, ntla:TwoThousandTwentyStockPurchaseAgreement


None
Period End2020-05-31
Value30
Percentage of SaleOfStockConsiderationReceivedOnTransaction100.0

us-gaap:SaleOfStockConsiderationReceivedOnTransaction us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

ntla:RegeneronPharmaceuticalsInc, ntla:TwoThousandTwentyStockPurchaseAgreement


None
Period End2020-05-30
Value30
Percentage of SaleOfStockConsiderationReceivedOnTransaction0.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue


None
Period End2020-06-302020-03-31
Value015.05
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue0.0100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
Value0.7020.667-0.0020.6750.6790.692-0.0180.8770.8770.8940.0090.9540.940.92600.0010.0020.8770.032
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.0100.0100.0100.0100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
Value0.0040.01-0.0010.0160.0210.0260.0010.0280.0280.0250.0010.0190.0150.0190000.0130.001
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.00.00.0100.0100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue


None
Period End2020-06-302020-03-312019-06-302019-03-31
Value0.50.31.30.1
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue100.0100.0100.0100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-30
Value9.047.9609.669.228.94-3.1421.2916.6418.281.713.4511.4710.380.0614.9113.574.980.273.97
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue100.0100.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans us-gaap:StatementEquityComponents

us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans

us-gaap:CommonStock


None
Period End2020-06-302019-06-302018-06-30
Value55296.045826.032707.0
Percentage of StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans100.0100.0100.0

us-gaap:StockIssuedDuringPeriodSharesNewIssues us-gaap:CounterpartyName, us-gaap:StatementEquityComponents, us-gaap:SubsidiarySaleOfStock

us-gaap:StockIssuedDuringPeriodSharesNewIssues

ntla:RegeneronPharmaceuticalsInc, us-gaap:CommonStock, us-gaap:PrivatePlacement


None
Period End2020-06-30
Value925220.0
Percentage of StockIssuedDuringPeriodSharesNewIssues100.0

us-gaap:StockIssuedDuringPeriodSharesNewIssues us-gaap:CounterpartyName, us-gaap:SubsidiarySaleOfStock, us-gaap:TypeOfArrangement

ntla:RegeneronPharmaceuticalsInc, us-gaap:PrivatePlacement, ntla:TwoThousandTwentyStockPurchaseAgreement


None
Period End2020-05-31
Value925220.0
Percentage of StockIssuedDuringPeriodSharesNewIssues0.0

us-gaap:StockIssuedDuringPeriodSharesNewIssues us-gaap:StatementEquityComponents

us-gaap:CommonStock


None
Period End2020-03-312019-09-302019-06-302019-03-312016-12-312016-09-30
Value351250.01141400.01986600.0223820.000
Percentage of StockIssuedDuringPeriodSharesNewIssues0.00.00.00.00.00.0

us-gaap:StockIssuedDuringPeriodSharesNewIssues us-gaap:StatementEquityComponents, us-gaap:SubsidiarySaleOfStock

us-gaap:CommonStock, ntla:AtMarketOffering


None
Period End2020-06-302020-03-312019-06-302019-03-31
Value755850.0351250.01986600.0223820.0
Percentage of StockIssuedDuringPeriodSharesNewIssues81.70.00.00.0

us-gaap:CommonStock, ntla:FollowOnPublicOffering


None
Period End2020-06-30
Value6301400.0
Percentage of StockIssuedDuringPeriodSharesNewIssues681.1

us-gaap:StockIssuedDuringPeriodSharesNewIssues us-gaap:SubsidiarySaleOfStock, us-gaap:TypeOfArrangement

ntla:FollowOnPublicOffering, ntla:UnderwritingAgreement


None
Period End2020-06-01
Value6301400.0
Percentage of StockIssuedDuringPeriodSharesNewIssues0.0

us-gaap:StockIssuedDuringPeriodSharesNewIssues us-gaap:TypeOfArrangement

ntla:TwoThousandNineteenSalesAgreement


None
Period End2020-06-302020-03-312019-12-31
Value755850.0351250.0287230.0
Percentage of StockIssuedDuringPeriodSharesNewIssues81.70.00.0

us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised

us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
Value83631.053579.0109220.021311.0203070.030800.0
Percentage of StockIssuedDuringPeriodSharesStockOptionsExercised100.0100.0100.0100.0100.0100.0

us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised us-gaap:StatementEquityComponents

us-gaap:CommonStock


None
Period End2020-06-302020-03-312019-09-302019-06-302019-03-312018-09-302018-06-302018-03-31
Value83631.053579.021311.0203070.030800.0204660.068163.0709320.0
Percentage of StockIssuedDuringPeriodSharesStockOptionsExercised100.0100.0100.0100.0100.00.00.00.0

us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan

us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan


None
Period End2020-06-302019-06-302018-06-30
Value685000.0534000.0598000.0
Percentage of StockIssuedDuringPeriodValueEmployeeStockPurchasePlan100.0100.0100.0

us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan us-gaap:StatementEquityComponents

us-gaap:AdditionalPaidInCapital


None
Period End2020-06-302019-06-302018-06-30
Value685000.0534000.0598000.0
Percentage of StockIssuedDuringPeriodValueEmployeeStockPurchasePlan100.0100.0100.0

us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised

us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised


None
Period End2020-06-302020-03-312019-09-302019-06-302019-03-312018-09-302018-06-302018-03-31
Value1.0350.3360.1921.6640.362.180.5576.72
Percentage of StockIssuedDuringPeriodValueStockOptionsExercised100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised us-gaap:StatementEquityComponents

us-gaap:AdditionalPaidInCapital


None
Period End2020-06-302020-03-312019-09-302019-06-302019-03-312018-09-302018-06-302018-03-31
Value1.0350.3360.1921.6640.362.180.5576.72
Percentage of StockIssuedDuringPeriodValueStockOptionsExercised100.0100.0100.0100.0100.0100.0100.0100.0

ntla:AccruedResearchAndDevelopmentExpensesCurrent

ntla:AccruedResearchAndDevelopmentExpensesCurrent


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312017-12-31
Value7160000.06324000.04208000.02911000.02485000.02231000.02328000.01960000.0
Percentage of AccruedResearchAndDevelopmentExpensesCurrent100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:AccountsReceivableNet us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

us-gaap:AccountsReceivableNet

ntla:NovartisInstitutesForBioMedicalResearchInc, ntla:RegeneronArrangement


None
Period End2020-06-302020-03-312019-12-31
Value05000000.01000000.0
Percentage of AccountsReceivableNet0.0100.0100.0

us-gaap:AccountsReceivableRelatedParties us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

us-gaap:AccountsReceivableRelatedParties

ntla:RegeneronPharmaceuticalsInc, ntla:RegeneronAmendment


None
Period End2020-06-302019-12-31
Value3900000.03600000.0
Percentage of AccountsReceivableRelatedParties100.0100.0

ntla:RegeneronPharmaceuticalsInc, ntla:RegeneronArrangement


None
Period End2020-03-312019-12-31
Value8400000.03600000.0
Percentage of AccountsReceivableRelatedParties0.0100.0

us-gaap:AccruedProfessionalFeesCurrent

us-gaap:AccruedProfessionalFeesCurrent


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
Value1892000.02535000.01563000.02663000.04837000.01946000.01633000.04774000.05215000.03845000.03226000.02808000.03227000.02027000.03197000.02936000.02907000.01948000.0907000.0
Percentage of AccruedProfessionalFeesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:AssetsFairValueDisclosure us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency

us-gaap:AssetsFairValueDisclosure

us-gaap:FairValueInputsLevel1, us-gaap:FairValueMeasurementsRecurring


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
Value395179206212192207211289300313330
Percentage of AssetsFairValueDisclosure100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsRecurring


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value33676780798289
Percentage of AssetsFairValueDisclosure8.537.632.838.041.539.942.1

us-gaap:AssetsFairValueDisclosure us-gaap:FairValueByMeasurementFrequency

us-gaap:FairValueMeasurementsRecurring


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
Value429246274292272290301289300313330
Percentage of AssetsFairValueDisclosure108.5137.6132.8138.0141.5139.9142.1100.0100.0100.0100.0

us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value155000.0401000.0262000.0341000.0255000.059000.03000.0
Percentage of AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax100.0100.0100.0100.0100.0100.0100.0

us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax us-gaap:FinancialInstrument

ntla:FinancialInstitutionDebtSecurities


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value80000.020000.0105000.0124000.069000.025000.01000.0
Percentage of AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax51.65.040.136.427.142.433.3

us-gaap:USTreasurySecurities


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value75000.0381000.0142000.0188000.0161000.033000.02000.0
Percentage of AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax48.495.054.255.163.155.966.7

us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax


None
Period End2020-03-312019-12-312019-09-302018-12-31
Value27000.01000.05000.031000.0
Percentage of AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax100.0100.0100.0100.0

us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax us-gaap:FinancialInstrument

ntla:FinancialInstitutionDebtSecurities


None
Period End2020-03-312018-12-31
Value27000.017000.0
Percentage of AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax100.054.8

us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis

us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value74168226257226249255
Percentage of AvailableForSaleDebtSecuritiesAmortizedCostBasis100.0100.0100.0100.0100.0100.0100.0

us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis us-gaap:FinancialInstrument

ntla:FinancialInstitutionDebtSecurities


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value28544053536565
Percentage of AvailableForSaleDebtSecuritiesAmortizedCostBasis38.032.017.720.923.426.325.6

us-gaap:AssetBackedSecurities


None
Period End2020-03-312019-12-312019-09-302019-06-30
Value8.4998.4857.9727.958
Percentage of AvailableForSaleDebtSecuritiesAmortizedCostBasis5.03.73.13.5

us-gaap:CorporateDebtSecurities


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value4.9634.9421818181623
Percentage of AvailableForSaleDebtSecuritiesAmortizedCostBasis6.62.98.47.48.36.89.3

us-gaap:USTreasurySecurities


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value41101159176146166165
Percentage of AvailableForSaleDebtSecuritiesAmortizedCostBasis55.360.170.268.764.766.965.0

us-gaap:AvailableForSaleSecuritiesDebtSecurities

us-gaap:AvailableForSaleSecuritiesDebtSecurities


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value75169227257226249255
Percentage of AvailableForSaleSecuritiesDebtSecurities100.0100.0100.0100.0100.0100.0100.0

us-gaap:AvailableForSaleSecuritiesDebtSecurities us-gaap:FinancialInstrument

ntla:FinancialInstitutionDebtSecurities


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value28544053536565
Percentage of AvailableForSaleSecuritiesDebtSecurities38.131.917.720.923.426.325.6

us-gaap:AssetBackedSecurities


None
Period End2020-03-312019-12-312019-09-302019-06-30
Value8.4998.4997.9957.983
Percentage of AvailableForSaleSecuritiesDebtSecurities5.03.73.13.5

us-gaap:CorporateDebtSecurities


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value4.9634.9421818181623
Percentage of AvailableForSaleSecuritiesDebtSecurities6.62.98.37.38.36.89.3

us-gaap:USTreasurySecurities


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value41101159176146166165
Percentage of AvailableForSaleSecuritiesDebtSecurities55.360.170.268.664.766.965.0

us-gaap:CashAndCashEquivalentsFairValueDisclosure us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency

us-gaap:CashAndCashEquivalentsFairValueDisclosure

us-gaap:FairValueInputsLevel1, us-gaap:FairValueMeasurementsRecurring


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
Value354774635454045289300313330
Percentage of CashAndCashEquivalentsFairValueDisclosure100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:CashAndCashEquivalentsFairValueDisclosure us-gaap:FairValueByMeasurementFrequency

us-gaap:FairValueMeasurementsRecurring


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
Value354774635454045289300313330
Percentage of CashAndCashEquivalentsFairValueDisclosure100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302017-12-312016-12-31
Value363805738494758293305340273
Percentage of CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:CommonStockCapitalSharesReservedForFutureIssuance us-gaap:PlanName

us-gaap:CommonStockCapitalSharesReservedForFutureIssuance

ntla:TwoThousandAndFifteenStockOptionAndIncentivePlan


None
Period End2020-06-30
Value2104700.0
Percentage of CommonStockCapitalSharesReservedForFutureIssuance100.0

us-gaap:CommonStockCapitalSharesReservedForFutureIssuance us-gaap:SubsidiarySaleOfStock, us-gaap:TypeOfArrangement

ntla:FollowOnPublicOffering, ntla:UnderwritingAgreement


None
Period End2020-06-01
Value821920.0
Percentage of CommonStockCapitalSharesReservedForFutureIssuance0.0

us-gaap:ContractWithCustomerLiability

us-gaap:ContractWithCustomerLiability


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
Value10025283542495546505559
Percentage of ContractWithCustomerLiability100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:ContractWithCustomerLiability us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

ntla:RegeneronPharmaceuticalsInc, ntla:RegeneronAmendment


None
Period End2020-06-302019-12-31
Value10028
Percentage of ContractWithCustomerLiability100.0100.0

ntla:RegeneronPharmaceuticalsInc, ntla:RegeneronArrangement


None
Period End2020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302017-12-31
Value2528323538414454
Percentage of ContractWithCustomerLiability100.2100.091.183.578.074.096.490.4

us-gaap:ContractWithCustomerLiabilityNoncurrent

us-gaap:ContractWithCustomerLiabilityNoncurrent


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302017-12-31
Value621316192225283144
Percentage of ContractWithCustomerLiabilityNoncurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:EmployeeRelatedLiabilitiesCurrent

us-gaap:EmployeeRelatedLiabilitiesCurrent


None
Period End2020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
Value5677000.03172000.06311000.02830000.06175000.05119000.03941000.02760000.04773000.03131000.02085000.01532000.02703000.01874000.01181000.0625000.01281000.0
Percentage of EmployeeRelatedLiabilitiesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:InvestmentsFairValueDisclosure us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency

us-gaap:InvestmentsFairValueDisclosure

us-gaap:FairValueInputsLevel1, us-gaap:FairValueMeasurementsRecurring


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value41101159176146166165
Percentage of InvestmentsFairValueDisclosure100.0100.0100.0100.0100.0100.0100.0

us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsRecurring


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value33676780798289
Percentage of InvestmentsFairValueDisclosure80.766.342.545.754.549.653.8

us-gaap:InvestmentsFairValueDisclosure us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument

us-gaap:FairValueInputsLevel1, us-gaap:FairValueMeasurementsRecurring, us-gaap:USTreasurySecurities


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302018-12-31
Value41101159176146165
Percentage of InvestmentsFairValueDisclosure100.0100.0100.0100.0100.0100.0

us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsRecurring, ntla:FinancialInstitutionDebtSecurities


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302018-12-31
Value285440535365
Percentage of InvestmentsFairValueDisclosure68.853.125.330.536.239.4

us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsRecurring, us-gaap:AssetBackedSecurities


None
Period End2020-03-312019-12-312019-09-302019-06-30
Value8.4998.4997.9957.983
Percentage of InvestmentsFairValueDisclosure8.35.34.55.4

us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsRecurring, us-gaap:CorporateDebtSecurities


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302018-12-31
Value4.9634.94218181823
Percentage of InvestmentsFairValueDisclosure11.94.911.910.712.914.4

us-gaap:InvestmentsFairValueDisclosure us-gaap:FairValueByMeasurementFrequency

us-gaap:FairValueMeasurementsRecurring


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value75169227257226249255
Percentage of InvestmentsFairValueDisclosure180.7166.3142.5145.7154.5149.6153.8

us-gaap:InvestmentsFairValueDisclosure us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument

us-gaap:FairValueMeasurementsRecurring, ntla:FinancialInstitutionDebtSecurities


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302018-12-31
Value285440535365
Percentage of InvestmentsFairValueDisclosure68.853.125.330.536.239.4

us-gaap:FairValueMeasurementsRecurring, us-gaap:AssetBackedSecurities


None
Period End2020-03-312019-12-312019-09-302019-06-30
Value8.4998.4997.9957.983
Percentage of InvestmentsFairValueDisclosure8.35.34.55.4

us-gaap:FairValueMeasurementsRecurring, us-gaap:CorporateDebtSecurities


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302018-12-31
Value4.9634.94218181823
Percentage of InvestmentsFairValueDisclosure11.94.911.910.712.914.4

us-gaap:FairValueMeasurementsRecurring, us-gaap:USTreasurySecurities


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302018-12-31
Value41101159176146165
Percentage of InvestmentsFairValueDisclosure100.0100.0100.0100.0100.0100.0

us-gaap:MarketableSecuritiesCurrent

us-gaap:MarketableSecuritiesCurrent


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302018-12-31
Value75169222247221255
Percentage of MarketableSecuritiesCurrent100.0100.0100.0100.0100.0100.0

us-gaap:RestrictedCashEquivalents

us-gaap:RestrictedCashEquivalents


None
Period End2020-06-30
Value1911000.0
Percentage of RestrictedCashEquivalents100.0

us-gaap:RevenueRemainingPerformanceObligation us-gaap:CounterpartyName, us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByType

us-gaap:RevenueRemainingPerformanceObligation

ntla:RegeneronPharmaceuticalsInc, us-gaap:LicenseAgreementTerms


None
Period End2020-06-30
Value15
Percentage of RevenueRemainingPerformanceObligation100.0

us-gaap:RevenueRemainingPerformanceObligation us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

ntla:RegeneronPharmaceuticalsInc, ntla:RegeneronAmendment


None
Period End2020-06-30
Value85
Percentage of RevenueRemainingPerformanceObligation557.5

us-gaap:SaleOfStockPricePerShare us-gaap:CounterpartyName, us-gaap:SubsidiarySaleOfStock, us-gaap:TypeOfArrangement

us-gaap:SaleOfStockPricePerShare

ntla:RegeneronPharmaceuticalsInc, us-gaap:PrivatePlacement, ntla:TwoThousandTwentyStockPurchaseAgreement


None
Period End2020-05-31
Value32.42
Percentage of SaleOfStockPricePerShare100.0

us-gaap:SaleOfStockPricePerShare us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

ntla:RegeneronPharmaceuticalsInc, ntla:TwoThousandTwentyStockPurchaseAgreement


None
Period End2020-05-30
Value32.42
Percentage of SaleOfStockPricePerShare0.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302015-12-31
Value248480.0248480.071875.071875.072611.079192.0109070.0143520.0261040.0399830.0479820.0765640.0981620.01174900.01361900.01550800.01764600.02227300.0
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue


None
Period End2020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302015-12-31
Value17.3117.3122.8822.8822.6620.8915.5312.138.375.020.90.840.840.820.810.80.80.81
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:SharesIssuedPricePerShare us-gaap:SubsidiarySaleOfStock, us-gaap:TypeOfArrangement

us-gaap:SharesIssuedPricePerShare

ntla:FollowOnPublicOffering, ntla:UnderwritingAgreement


None
Period End2020-06-01
Value18.25
Percentage of SharesIssuedPricePerShare100.0

us-gaap:SharesIssuedPricePerShare us-gaap:TypeOfArrangement

ntla:TwoThousandNineteenSalesAgreement


None
Period End2020-06-302020-03-312019-12-31
Value13.7815.0516.48
Percentage of SharesIssuedPricePerShare0.00.00.0

Line plots across dimensions of each concept


us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecurities
(None,)
None
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement
(None, 'ntla:RegeneronArrangement')
None
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement
('ntla:NovartisInstitutesForBioMedicalResearchInc', None)
None
us-gaap:AllocatedShareBasedCompensationExpense
us-gaap:IncomeStatementLocation
(None,)
None
us-gaap:StockholdersEquity
us-gaap:StatementEquityComponents
(None,)
None
us-gaap:StockholdersEquity
us-gaap:StatementEquityComponents
(None,)
None